Unlike Contrave, Wegovy comes as a weekly subcutaneous (under the skin) injection
[36], in a real-world cohort treated with GLP-1 RAs including exenatide, observed a mean BW loss of 2.5 kg and a BMI reduction of 0.9 kg/m without a significant change in intrahepatic lipid content, reflecting variability in hepatic responses across populations
Patients who do not have diabetes or only take semaglutide for weight loss generally do not need to worry about hypoglycemia during exercise
Yes, they suppress your appetite
If the above measures are not as efficient as expected, either a decrease in GLP-1 RA dose or a temporary interruption of the treatment may be considered [35]
Early results from ongoing clinical studies are indicating the GLP-1 medications may successfully treat numerous other conditions including non-alcoholic fatty liver disease (known as metabolic dysfunction-associated steatohepatitis or MASH), sleep apnea, heart failure, diabetic kidney disease and Alzheimers disease